{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:33:27Z","timestamp":1768566807742,"version":"3.49.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cranio-Maxillofacial Surgery"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.jcms.2012.01.028","type":"journal-article","created":{"date-parts":[[2012,3,17]],"date-time":"2012-03-17T15:02:30Z","timestamp":1331996550000},"page":"e369-e374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Dexrazoxane shows cytoprotective effects in zoledronic acid-treated human cells in\u00a0vitro and in the rabbit tibia model in\u00a0vivo"],"prefix":"10.1016","volume":"40","author":[{"given":"G.F.","family":"Draenert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.O.","family":"Huetzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.W.","family":"K\u00e4mmerer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Palarie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Nacu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcms.2012.01.028_bib1","unstructured":"Acil Y, Moller B, Niehoff P, Rachko K, Gassling V, Wiltfang J, et\u00a0al.: The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells. J Craniomaxillofac Surg, in press."},{"key":"10.1016\/j.jcms.2012.01.028_bib2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.14219\/jada.archive.2007.0294","article-title":"The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors","volume":"138","author":"Adornato","year":"2007","journal-title":"J\u00a0Am Dent Assoc"},{"key":"10.1016\/j.jcms.2012.01.028_bib3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/mutage\/ger013","article-title":"Salubrious effects of dexrazoxane against teniposide-induced DNA damage and programmed cell death in murine marrow cells","volume":"26","author":"Bakheet","year":"2011","journal-title":"Mutagenesis"},{"key":"10.1016\/j.jcms.2012.01.028_bib4","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/(SICI)1099-081X(199608)17:6<541::AID-BDD975>3.0.CO;2-5","article-title":"Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs","volume":"17","author":"Baldwin","year":"1996","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.jcms.2012.01.028_bib5","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.2007.12.2481","article-title":"Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane","volume":"26","author":"Barry","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jcms.2012.01.028_bib6","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1200\/JCO.1994.12.8.1659","article-title":"Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy","volume":"12","author":"Basser","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jcms.2012.01.028_bib7","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.biomaterials.2011.09.092","article-title":"The effect of zoledronate-hydroxyapatite nanocomposites on osteoclasts and osteoblast-like cells in\u00a0vitro","volume":"33","author":"Boanini","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jcms.2012.01.028_bib8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/03008200290000934","article-title":"Changes in bone remodeling rate influence the degree of mineralization of bone","volume":"43","author":"Boivin","year":"2002","journal-title":"Connect Tissue Res"},{"key":"10.1016\/j.jcms.2012.01.028_bib9","first-page":"538","article-title":"Effects of bisphosphonates on matrix mineralization","volume":"2","author":"Boivin","year":"2002","journal-title":"J\u00a0Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.jcms.2012.01.028_bib10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025","volume":"22","author":"Burge","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.jcms.2012.01.028_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006647.pub2","article-title":"Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer","author":"van Dalen","year":"2009","journal-title":"Cochrane Database Syst"},{"key":"10.1016\/j.jcms.2012.01.028_bib12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1470-2045(10)70301-6","article-title":"Should anthracyclines and dexrazoxane be used for children with cancer?","volume":"12","author":"van Dalen","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcms.2012.01.028_bib13","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(11)70030-4","article-title":"Preventive therapy for breast cancer: a consensus statement","volume":"12","author":"Cuzick","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcms.2012.01.028_bib14","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/019262339602400402","article-title":"Long-lasting effect of dexrazoxane against anthracycline cardiotoxicity in rats","volume":"24","author":"Della","year":"1996","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.jcms.2012.01.028_bib15","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1600-0714.1982.tb00172.x","article-title":"A\u00a0method for the study of undecalcified bones and teeth with attached soft tissues. The Sage-Schliff (sawing and grinding) technique","volume":"11","author":"Donath","year":"1982","journal-title":"J\u00a0Oral Pathol"},{"key":"10.1016\/j.jcms.2012.01.028_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/j.1552-4604.1998.tb04397.x","article-title":"Chelation therapy in cardiovascular disease: ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane","volume":"38","author":"Elihu","year":"1998","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jcms.2012.01.028_bib17","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.tripleo.2010.05.067","article-title":"Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series","volume":"110","author":"Epstein","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.jcms.2012.01.028_bib18","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.joms.2010.10.055","article-title":"Preventive protocol for tooth extractions in patients treated with zoledronate: a case series","volume":"69","author":"Ferlito","year":"2011","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.jcms.2012.01.028_bib19","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s10529-011-0542-7","article-title":"Co-loading of bisphosphonates and antibiotics to a biomimetic hydroxyapatite coating","volume":"33","author":"Forsgren","year":"2011","journal-title":"Biotechnol Lett"},{"key":"10.1016\/j.jcms.2012.01.028_bib20","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1200\/JCO.2011.35.1551","article-title":"Osteonecrosis of the jaw after zoledronic acid and denosumab treatment","volume":"29","author":"Fusco","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jcms.2012.01.028_bib21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.biopha.2009.06.018","article-title":"In\u00a0vitro and in\u00a0vivo study on the antioxidant activity of dexrazoxane","volume":"64","author":"Galetta","year":"2010","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jcms.2012.01.028_bib22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11912-010-0088-1","article-title":"RANK ligand: effects of inhibition","volume":"12","author":"George","year":"2010","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jcms.2012.01.028_bib23","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/pds.1245","article-title":"Developments of the incidence of osteoporosis in The Netherlands: a PHARMO study","volume":"16","author":"Goettsch","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Suppl. 4","key":"10.1016\/j.jcms.2012.01.028_bib24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","article-title":"Bisphosphonates: preclinical review","volume":"9","author":"Green","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.jcms.2012.01.028_bib25","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/RHU.0b013e31816d84b8","article-title":"Prior bisphosphonate therapy of osteoporosis attenuates and blocks response to subsequent parathyroid hormone","volume":"14","author":"Handler","year":"2008","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.jcms.2012.01.028_bib26","first-page":"3","article-title":"Chemistry of dexrazoxane and analogues","volume":"25","author":"Hasinoff","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jcms.2012.01.028_bib27","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00001813-199806000-00014","article-title":"The one-ring open hydrolysis intermediates of the cardioprotective agent dexrazoxane (ICRF-187) do not inhibit the growth of Chinese hamster ovary cells or the catalytic activity of DNA topoisomerase II","volume":"9","author":"Hasinoff","year":"1998","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jcms.2012.01.028_bib28","first-page":"48","article-title":"Overview and historical development of dexrazoxane","volume":"25","author":"Hellmann","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jcms.2012.01.028_bib29","series-title":"Osteoporosis & bone metabolism disorders: world market 2010\u20132025","author":"Visiongain Inc.","year":"2010"},{"key":"10.1016\/j.jcms.2012.01.028_bib30","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.jcms.2012.01.028_bib31","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.joms.2008.01.054","article-title":"Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"66","author":"Khosla","year":"2008","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.jcms.2012.01.028_bib32","first-page":"277","article-title":"Oral bisphosphonate-related osteonecrosis of the jaws: favorable outcome after bisphosphonate holiday","volume":"40","author":"Kwon","year":"2009","journal-title":"Quintessence Int"},{"key":"10.1016\/j.jcms.2012.01.028_bib33","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1002\/cncr.20652","article-title":"Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades","volume":"101","author":"Kyle","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jcms.2012.01.028_bib34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcms.2010.03.002","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a review of 34 cases and evaluation of risk","volume":"39","author":"Kyrgidis","year":"2011","journal-title":"J\u00a0Craniomaxillofac Surg"},{"key":"10.1016\/j.jcms.2012.01.028_bib35","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa035153","article-title":"The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia","volume":"351","author":"Lipshultz","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcms.2012.01.028_bib36","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1470-2045(10)70204-7","article-title":"Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial","volume":"11","author":"Lipshultz","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcms.2012.01.028_bib37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1155\/MBD.1997.199","article-title":"Fe-EDTA-Bisamide and Fe-ADR-925, The Iron-Bound Hydrolysis Product of the Cardioprotective Agent Dexrazoxane, Cleave DNA Via the Hydroxyl Radical","volume":"4","author":"Magliery","year":"1997","journal-title":"Met Based Drugs"},{"key":"10.1016\/j.jcms.2012.01.028_bib38","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.oraloncology.2011.02.017","article-title":"Comments on \u201cGeranylgeraniol \u2013 a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw\" by Ziebart T et\u00a0al. (2011)","volume":"47","author":"Marcuzzi","year":"2011","journal-title":"Oral Oncol"},{"key":"10.1016\/j.jcms.2012.01.028_bib39","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.jcms.2012.01.028_bib40","unstructured":"Mast G, Otto S, Mucke T, Schreyer C, Bissinger O, Kolk A, et\u00a0al.: Incidence of maxillary sinusitis and oro-antral fistulae in bisphosphonate-related osteonecrosis of the jaw. J Craniomaxillofac Surg, in press."},{"key":"10.1016\/j.jcms.2012.01.028_bib41","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.jcms.2012.01.028_bib42","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/104345429701400208","article-title":"Dexrazoxane (ICRF-187): a cardioprotective agent during anthracycline chemotherapy","volume":"14","author":"O\u2019Marcaigh","year":"1997","journal-title":"J\u00a0Pediatr Oncol Nurs"},{"key":"10.1016\/j.jcms.2012.01.028_bib43","unstructured":"Otto S, Schreyer C, Hafner S, Mast G, Ehrenfeld M, Sturzenbaum S, et\u00a0al.: Bisphosphonate-related osteonecrosis of the jaws \u2013 characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg, in press."},{"key":"10.1016\/j.jcms.2012.01.028_bib44","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2141.2004.05207.x","article-title":"A\u00a0population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK","volume":"127","author":"Phekoo","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcms.2012.01.028_bib45","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/sj.bjc.6605192","article-title":"Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in\u00a0vivo: effective rescue of cardiomyocytes from apoptotic cell death","volume":"101","author":"Popelova","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jcms.2012.01.028_bib46","series-title":"Global osteoporosis therapeutics market to reach US$11.1 billion by 2010, according to new report by global industry analysts","author":"PR-Newswire-Europe-Ltd.","year":"2008"},{"key":"10.1016\/j.jcms.2012.01.028_bib47","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","article-title":"Osteoporosis: now and the future","volume":"377","author":"Rachner","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jcms.2012.01.028_bib48","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.bone.2008.01.003","article-title":"Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis","volume":"42","author":"Rizzoli","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.jcms.2012.01.028_bib49","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcms.2012.01.028_bib50","unstructured":"Saad F, Brown JE, Van PC, Ibrahim T, Stemmer SM, Stopeck AT, et\u00a0al.: Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol, in press."},{"key":"10.1016\/j.jcms.2012.01.028_bib51","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2008-04-147884","article-title":"Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis","volume":"112","author":"Sarasquete","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jcms.2012.01.028_bib52","doi-asserted-by":"crossref","first-page":"61","DOI":"10.14219\/jada.archive.2009.0019","article-title":"Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry","volume":"140","author":"Sedghizadeh","year":"2009","journal-title":"J\u00a0Am Dent Assoc"},{"key":"10.1016\/j.jcms.2012.01.028_bib53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00784-009-0312-2","article-title":"Expression profile and synthesis of different collagen types I, II, III, and V of human gingival fibroblasts, osteoblasts, and SaOS-2 cells after bisphosphonate treatment","volume":"14","author":"Simon","year":"2010","journal-title":"Clin Oral Investig"},{"key":"10.1016\/j.jcms.2012.01.028_bib54","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jcms.2012.01.028_bib55","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws","volume":"65","author":"Surgeons, AAoOaM","year":"2007","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.jcms.2012.01.028_bib56","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1200\/JCO.1997.15.4.1333","article-title":"Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy","volume":"15","author":"Swain","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jcms.2012.01.028_bib57","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1200\/JCO.2005.02.3879","article-title":"Dexrazoxane-associated risk for acute myeloid leukemia\/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin\u2019s disease","volume":"25","author":"Tebbi","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jcms.2012.01.028_bib58","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1158\/1078-0432.CCR-07-0079","article-title":"Therapeutic role of bisphosphonate and radiation combination in the management of myeloma bone disease","volume":"13","author":"Ural","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcms.2012.01.028_bib59","first-page":"181","article-title":"Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy. A critical review","volume":"59","author":"Vescovi","year":"2010","journal-title":"Minerva Stomatol"},{"key":"10.1016\/j.jcms.2012.01.028_bib60","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0006-2952(96)00894-5","article-title":"Modulation of transferrin receptor expression by dexrazoxane (ICRF-187) via activation of iron regulatory protein","volume":"53","author":"Weiss","year":"1997","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jcms.2012.01.028_bib61","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pain.2009.09.006","article-title":"Olesoxime (cholest-4-en-3-one, oxime): analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel","volume":"147","author":"Xiao","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.jcms.2012.01.028_bib62","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.oraloncology.2010.12.003","article-title":"Geranylgeraniol \u2013 a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw","volume":"47","author":"Ziebart","year":"2011","journal-title":"Oral Oncol"},{"key":"10.1016\/j.jcms.2012.01.028_bib63","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00784-009-0365-2","article-title":"Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in\u00a0vitro","volume":"15","author":"Ziebart","year":"2009","journal-title":"Clin Oral Investig"}],"container-title":["Journal of Cranio-Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1010518212000443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1010518212000443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T14:27:25Z","timestamp":1760884045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1010518212000443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":63,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S1010518212000443"],"URL":"https:\/\/doi.org\/10.1016\/j.jcms.2012.01.028","relation":{},"ISSN":["1010-5182"],"issn-type":[{"value":"1010-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dexrazoxane shows cytoprotective effects in zoledronic acid-treated human cells in\u00a0vitro and in the rabbit tibia model in\u00a0vivo","name":"articletitle","label":"Article Title"},{"value":"Journal of Cranio-Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcms.2012.01.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}